Loss of REV-ERBα or its pharmacological inhibition potently blocks NEPC tumor growth and abolishes tumor LP feature, thus making REV-ERBα an attractive therapeutic target for effective treatment of advanced tumors featuring LP such as NEPC. This evidence concerns the gene NR1D1 and neoplasm.